Elzsírosodása

Elzsírosodása refers to the abnormal accumulation of fat in organs or tissues that are not typically storing large amounts of fat. The most common and clinically significant form is hepatic elzsírosodása, also known as fatty liver disease. This condition occurs when fat droplets build up within liver cells, impairing liver function.

There are two main types of fatty liver disease: alcoholic fatty liver disease, caused by excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). NAFLD is increasingly prevalent worldwide and is often associated with metabolic risk factors such as obesity, type 2 diabetes, high cholesterol, and high triglycerides.

Symptoms of elzsírosodása are often absent, especially in the early stages. However, when symptoms do occur, they can include fatigue, weakness, abdominal pain, and jaundice. In advanced stages, particularly with NAFLD, it can progress to non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, and liver cancer.

Diagnosis typically involves blood tests to assess liver enzymes, imaging studies like ultrasound or CT scans to visualize fat in the liver, and sometimes a liver biopsy for a definitive diagnosis and staging.

Treatment for elzsírosodása focuses on addressing the underlying causes. For alcoholic fatty liver disease, abstinence from alcohol is crucial. For NAFLD, lifestyle modifications such as weight loss, a healthy diet, and regular exercise are the cornerstone of management. Medications may be used to manage associated conditions like diabetes and high cholesterol.